861514-69-4

Basic information

• Product Name: Benzoic acid, 3-bromo-5-formyl-2-hydroxy-, methyl ester
• CAS NO: 861514-69-4
• Molecular Formula: C9H7BrO4
• Molecular Weight: 259.056
• Mol File: 861514-69-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 3-bromo-5-formyl-2-hydroxy-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-bromo-5-formyl-2-hydroxy-, methyl ester(861514-69-4)
• EPA Substance Registry System: Benzoic acid, 3-bromo-5-formyl-2-hydroxy-, methyl ester(861514-69-4)

Safety Data

• Hazardous Substances Data: 861514-69-4(Hazardous Substances Data)

Upstream product

• 616-76-2 2-hydroxy-5-formylbenzoic acid 
• 41489-76-3 methyl-5-formyl-2-hydroxybenzoate 

Downstream Products

• 914079-27-9 3-bromo-5-formyl-2-(3-nitro-benzyloxy)-benzoic acid methyl ester 
• 1072937-60-0 3-bromo-5-formyl-2-methoxybenzoic acid methyl ester 
• 1072937-61-1 5-formyl-2-hydroxybiphenyl-3-carboxylic acid methyl ester 
• 1621260-89-6 3-bromo-5-(2-chloro-benzyl)-2-hydroxybenzoic acid methyl ester 
• 1621260-90-9 2-bromo-4-(2-chloro-benzyl)-6-hydroxymethylphenol 
• 1208884-75-6 2-bromo-4-(2-chloro-benzyl)-6-hydroxymethylphenol 
• 378763-53-2 3-bromo-5-(2-chloro-benzyl)-2-hydroxybenzaldehyde 
• 384825-09-6 furan-2-carboxylic acid (4-{[3-bromo-5-(2-chlorobenzyl)-2-hydroxybenzylidene]amino}phenyl)amide 
• 914079-32-6 3-bromo-5-(3-cyano-2-methyl-5-oxo-7-propyl-1,4,5,6,7,8-hexahydro-quinolin-4-yl)-2-(3-methoxy-benzyloxy)-benzoic acid 

Relevant articles and documents

WDR5 INHIBITORS AND MODULATORS

Quinazolin-4(3H)-one, 2,3 -dihydroquinazolin-4(1H)-one, 3,4-dihydrobenzo[f][1,4]oxazepin- 5(2H)-one, and 3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione compounds and derivatives inhibit WDR5 and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.

Derivatives of 1,4-bis(3-hydroxycarbonyl-4-hydroxyl)styrylbenzene as PTP1B inhibitors with hypoglycemic activity

Disalicylic acid derivatives with stilbene and bis-styrylbenzene skeleton were synthesized as PTP1B inhibitors. The most potent in this series exhibited a submicromolar IC50 value. One of the compounds 7b was tested in an animal model for its efficacy as an anti-diabetic or an anti-obesity agent. In feeding compound 7b to diet-induced obese mice, no significant differences in weight gain and food consumption were observed between the drug-treated and the obese control mice. However, 7b significantly lowered the fasting glucose level and improved the glucose tolerance in the obesity-induced diabetic mice.

Mono- and disalicylic acid derivatives: PTP1B inhibitors as potential anti-obesity drugs

A series of compounds containing one or two salicylic acid moieties were synthesized, and their efficacy to inhibit the phosphohydrolase activity of PTP1B examined. Some of the methylenedisalicylic acid derivatives were potent inhibitors of PTP1B. Of those derivatives, 3c exhibited about a 14-fold selectivity against TC-PTP, and this compound was tested in a mouse model for its efficacy to prevent diet-induced obesity. It effectively suppressed the increases in body weight and adipose mass, without any noticeable toxic effect. The compound also prevented increases in the plasma triglyceride, cholesterol, and nonesterified fatty acid concentrations; thus, expanding its therapeutic potential to other related metabolic diseases, such as hyperlipidemia and hypercholesterolemia.